Skip to main content
Premium Trial:

Request an Annual Quote

Drug Discovery Startup Engine Biosciences Raises $10M

NEW YORK (GenomeWeb) – Drug discovery startup Engine Biosciences announced today that it has raised $10 million in seed funding.

The oversubscribed round was co-led by Danhua Capital and 6 Dimensions Capital, and included WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest Bio Ventures.

Engine said it would use the funding to continue development of its drug discovery platform, which combines high-throughput wet lab experimentation with artificial intelligence algorithms, as well as to expand its scientific and executive teams in Singapore and San Francisco. The company also aims to conduct preclinical studies internally and with partners.

"Engine's data-driven platform allows researchers to uncover the critical gene interactions underlying diseases and also test therapies that specifically target these interactions in a faster, cheaper, and more precise fashion than currently possible," Engine Cofounder and CEO Jeffrey Lu said in a statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.